drugset / Trial / NCT07549958
PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC)
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase 1, open-label clinical trial determining the recommended Phase 2 dose of Gemcitabine with Nab-paclitazel with or without Pitavastatin in subjects with unresectable pancreatic adenocarcinoma (uPDAC). These are subjects who are already receiving Gemcitabine for treatment of their disease.
Timeline
- Start
- 2026-03-24
- Primary completion
- 2027-03-31
- Completion
- 2028-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pitavastatin | Small molecule | 1 mg | Oral |
| Subject | Pitavastatin | Small molecule | 2 mg | Oral |
| Subject | Pitavastatin | Small molecule | 4 mg | Oral |